JP2019524140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524140A5 JP2019524140A5 JP2019507817A JP2019507817A JP2019524140A5 JP 2019524140 A5 JP2019524140 A5 JP 2019524140A5 JP 2019507817 A JP2019507817 A JP 2019507817A JP 2019507817 A JP2019507817 A JP 2019507817A JP 2019524140 A5 JP2019524140 A5 JP 2019524140A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- exon
- region
- dgkα
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 49
- 210000002865 immune cell Anatomy 0.000 claims 20
- 150000007523 nucleic acids Chemical group 0.000 claims 19
- 230000000295 complement effect Effects 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108091033409 CRISPR Proteins 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 6
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 claims 4
- 230000004957 immunoregulator effect Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 241000589875 Campylobacter jejuni Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000001814 protein method Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023004738A JP2023052426A (ja) | 2016-08-12 | 2023-01-16 | 操作された免疫調節エレメントおよび変更された免疫 |
| JP2024089774A JP2024113020A (ja) | 2016-08-12 | 2024-06-03 | 操作された免疫調節エレメントおよび変更された免疫 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0103308 | 2016-08-12 | ||
| KR1020160103308 | 2016-08-12 | ||
| US201762502822P | 2017-05-08 | 2017-05-08 | |
| US62/502,822 | 2017-05-08 | ||
| PCT/KR2017/008835 WO2018030874A1 (ko) | 2016-08-12 | 2017-08-14 | 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023004738A Division JP2023052426A (ja) | 2016-08-12 | 2023-01-16 | 操作された免疫調節エレメントおよび変更された免疫 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524140A JP2019524140A (ja) | 2019-09-05 |
| JP2019524140A5 true JP2019524140A5 (enExample) | 2020-09-24 |
| JP7215808B2 JP7215808B2 (ja) | 2023-01-31 |
Family
ID=65438099
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507817A Active JP7215808B2 (ja) | 2016-08-12 | 2017-08-14 | 操作された免疫調節エレメントおよび変更された免疫 |
| JP2023004738A Pending JP2023052426A (ja) | 2016-08-12 | 2023-01-16 | 操作された免疫調節エレメントおよび変更された免疫 |
| JP2024089774A Pending JP2024113020A (ja) | 2016-08-12 | 2024-06-03 | 操作された免疫調節エレメントおよび変更された免疫 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023004738A Pending JP2023052426A (ja) | 2016-08-12 | 2023-01-16 | 操作された免疫調節エレメントおよび変更された免疫 |
| JP2024089774A Pending JP2024113020A (ja) | 2016-08-12 | 2024-06-03 | 操作された免疫調節エレメントおよび変更された免疫 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12012598B2 (enExample) |
| EP (1) | EP3498846B1 (enExample) |
| JP (3) | JP7215808B2 (enExample) |
| KR (1) | KR102276371B1 (enExample) |
| CN (1) | CN109844118B (enExample) |
| AU (1) | AU2017308473B2 (enExample) |
| BR (1) | BR112019002779A2 (enExample) |
| CA (1) | CA3033736C (enExample) |
| ES (1) | ES2998057T3 (enExample) |
| RU (2) | RU2767206C2 (enExample) |
| SG (1) | SG11201901184QA (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| ES2998057T3 (en) | 2016-08-12 | 2025-02-18 | Toolgen Inc | Manipulated immunoregulatory element and immunity altered thereby |
| AU2018264636B2 (en) * | 2017-05-08 | 2022-03-17 | Toolgen Incorporated | Artificially manipulated immune cell |
| CN107164377A (zh) * | 2017-06-12 | 2017-09-15 | 王小平 | 基于碱基编辑的基因敲除方法及其应用 |
| US11441135B2 (en) * | 2017-07-07 | 2022-09-13 | Toolgen Incorporated | Target-specific CRISPR mutant |
| JP2021518160A (ja) * | 2018-03-15 | 2021-08-02 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| CN111321171A (zh) * | 2018-12-14 | 2020-06-23 | 江苏集萃药康生物科技有限公司 | 一种应用CRISPR/Cas9介导ES打靶技术制备基因打靶动物模型的方法 |
| CN110373385A (zh) * | 2019-07-12 | 2019-10-25 | 赛德特生物科技开发有限公司 | 改善神经细胞功能的免疫细胞培养基及其制备方法与应用 |
| CN114729325A (zh) * | 2019-09-06 | 2022-07-08 | 克里斯珀医疗股份公司 | 在培养物中具有改善的持久性的基因工程化t细胞 |
| US12152251B2 (en) * | 2020-08-25 | 2024-11-26 | Kite Pharma, Inc. | T cells with improved functionality |
| EP4291660A4 (en) * | 2021-02-10 | 2025-02-05 | Cartherics Pty. Ltd. | METHODS AND COMPOSITIONS FOR GENERATING STEM CELL-DERIVED IMMUNE CELLS WITH IMPROVED FUNCTION |
| CN114807044B (zh) * | 2021-04-30 | 2023-09-08 | 四川大学华西医院 | 一种具有高nkt细胞比例的car-cik细胞制备方法及应用 |
| CN115894706A (zh) * | 2021-09-30 | 2023-04-04 | 北京康辰药业股份有限公司 | 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| US20050221354A1 (en) * | 2004-02-18 | 2005-10-06 | Wyeth | Nucleic acid arrays for monitoring expression profiles of drug target genes |
| US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| CN102333277B (zh) | 2011-07-29 | 2014-08-06 | 上海合合信息科技发展有限公司 | 结合地理位置信息和蓝牙技术的电子名片传递方法及系统 |
| US20130129668A1 (en) * | 2011-09-01 | 2013-05-23 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
| PL4289948T3 (pl) | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| PT2898075E (pt) * | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências |
| WO2014093622A2 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| CN105658796B (zh) | 2012-12-12 | 2021-10-26 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| CN105121648B (zh) | 2012-12-12 | 2021-05-07 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| CN116083487A (zh) | 2013-05-15 | 2023-05-09 | 桑格摩生物治疗股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| CN105431524B (zh) * | 2013-06-10 | 2020-04-21 | 达娜-法勃肿瘤研究所公司 | 用于降低肿瘤细胞的免疫抑制的方法和组合物 |
| CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| US10836998B2 (en) | 2014-02-14 | 2020-11-17 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| WO2016011210A2 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| US10280402B2 (en) | 2014-08-06 | 2019-05-07 | College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation | Immune-compatible cells created by nuclease-mediated editing of genes encoding HLA |
| AU2015339743C1 (en) | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| US11470826B2 (en) | 2014-11-17 | 2022-10-18 | National University Corporation Tokyo Medical And Dental University | Method of conveniently producing genetically modified non-human mammal with high efficiency |
| JP6886404B2 (ja) | 2015-01-30 | 2021-06-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 初代造血細胞におけるタンパク質送達 |
| KR102888521B1 (ko) * | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| KR20180018457A (ko) | 2016-08-12 | 2018-02-21 | 주식회사 툴젠 | 조작된 면역조절요소 및 이에 의해 변형된 면역 활성 |
| ES2998057T3 (en) | 2016-08-12 | 2025-02-18 | Toolgen Inc | Manipulated immunoregulatory element and immunity altered thereby |
| CN110462034A (zh) | 2016-10-07 | 2019-11-15 | 综合Dna技术公司 | 化脓链球菌cas9突变基因和由其编码的多肽 |
| EP3336107A1 (en) | 2016-12-15 | 2018-06-20 | Miltenyi Biotec GmbH | Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor |
| AU2018264636B2 (en) | 2017-05-08 | 2022-03-17 | Toolgen Incorporated | Artificially manipulated immune cell |
| US12467050B2 (en) | 2017-10-02 | 2025-11-11 | Georgia Tech Research Corporation | Methods and compositions for engineering synthetic bioswitches for remote control of biological activity |
| SG11202005217VA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Phenotypic markers for cell therapy and related methods |
| WO2020014235A1 (en) | 2018-07-09 | 2020-01-16 | The Regents Of The University Of California | Gene targets for t-cell-based immunotherapy |
-
2017
- 2017-08-14 ES ES17839891T patent/ES2998057T3/es active Active
- 2017-08-14 CN CN201780063250.1A patent/CN109844118B/zh active Active
- 2017-08-14 BR BR112019002779-3A patent/BR112019002779A2/pt not_active Application Discontinuation
- 2017-08-14 RU RU2019106669A patent/RU2767206C2/ru active
- 2017-08-14 RU RU2022103870A patent/RU2022103870A/ru unknown
- 2017-08-14 AU AU2017308473A patent/AU2017308473B2/en active Active
- 2017-08-14 SG SG11201901184QA patent/SG11201901184QA/en unknown
- 2017-08-14 CA CA3033736A patent/CA3033736C/en active Active
- 2017-08-14 JP JP2019507817A patent/JP7215808B2/ja active Active
- 2017-08-14 US US16/324,955 patent/US12012598B2/en active Active
- 2017-08-14 EP EP17839891.3A patent/EP3498846B1/en active Active
-
2019
- 2019-06-11 KR KR1020190068999A patent/KR102276371B1/ko active Active
-
2023
- 2023-01-16 JP JP2023004738A patent/JP2023052426A/ja active Pending
-
2024
- 2024-05-07 US US18/657,145 patent/US20240301424A1/en active Pending
- 2024-06-03 JP JP2024089774A patent/JP2024113020A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524140A5 (enExample) | ||
| JP2019115348A5 (enExample) | ||
| IL295858B2 (en) | gRNA molecules including TRACR and crRNA, compositions containing them and their use | |
| RU2019106669A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
| JP2017505117A5 (enExample) | ||
| AU2024266825A1 (en) | Expression of human FOXP3 in gene edited T cells | |
| JP2018534950A5 (enExample) | ||
| JP2010523099A5 (enExample) | ||
| HRP20211468T1 (hr) | Postupci i pripravci za nukleazno posredovani inženjering genoma i ispravak u krvotvornim matičnim stanicama | |
| JP2018522566A5 (enExample) | ||
| CN102558309B (zh) | 一对转录激活子样效应因子核酸酶及其编码基因与应用 | |
| JP2012520085A5 (enExample) | ||
| CN106701808A (zh) | Dna聚合酶i缺陷型菌株及其构建方法 | |
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| CN107532182A (zh) | 治疗血红蛋白病的材料和方法 | |
| JP2019508051A5 (enExample) | ||
| CN106479985A (zh) | 病毒介导的Cpf1蛋白在CRISPR/Cpf1基因编辑系统中的应用 | |
| CN102703424B (zh) | 一种重组工程介导的大肠杆菌基因组点突变的方法 | |
| JP2011004753A5 (enExample) | ||
| JP2009501530A5 (enExample) | ||
| JP2016504026A5 (enExample) | ||
| JP2018528237A5 (enExample) | ||
| JP2013507934A5 (enExample) | ||
| JPWO2020163365A5 (enExample) |